MedPath

Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty

Not Applicable
Completed
Conditions
Knee Osteoarthritis
Interventions
Device: Neuromuscular electrical stimulation
Registration Number
NCT03051984
Lead Sponsor
University of Vermont
Brief Summary

Total knee replacement, or arthroplasty, is the final clinical intervention available to relieve pain and functional limitations related to advanced stage knee osteoarthritis. Despite its beneficial effects, the early post-surgical period is characterized by the erosion of lower extremity muscle size and strength that cause further disability and slow functional recovery. While the detrimental effects of this period on muscle are widely recognized, the mechanisms underlying these adaptations are poorly understood and there are currently no widely-accepted clinical interventions to counter them

Detailed Description

Total knee arthroplasty (TKA) is currently the most common elective surgery in the US and will increase in frequency nearly five-fold by 2030 to 3.5 million surgeries annually. This surgery is most prevalent among older adults with advanced knee osteoarthritis (OA) and its increase is explained primarily by growth in this population. Although TKA reliably reduces joint pain, it fails to correct objectively-measured functional disability due, in part, to dramatic declines in lower-extremity neuromuscular function during the early, postsurgical period. These deficits are never fully remediated, remaining for years after surgery and contributing to persistent disability. Despite these detrimental effects of TKA, the fundamental skeletal muscle adaptations that occur in the early, post-surgical period are poorly defined and understudied and there is currently no widely-accepted, evidence-based intervention to counter these changes. To address this clinical problem, the investigators goals in this application are to define the skeletal muscle structural and functional adaptations following TKA at the whole body, tissue, cellular, organellar and molecular levels in humans in an effort to identify factors contributing to functional disability and to assess the utility of neuromuscular electrical stimulation (NMES) to counter post-surgical muscle adaptations at these same anatomic levels. We hypothesize that TKA fails to remediate physical disability in patients, in part, because of the profound skeletal muscle myofilament and mitochondrial loss and dysfunction that develops during the early, post-surgical period. Moreover, the investigators posit that NMES will improve functional recovery following TKA by countering these early skeletal muscle adaptations. To test this model, the investigators will evaluate participants with knee OA prior to and following TKA for skeletal muscle structure and function at multiple anatomic levels, with patients randomized to receive NMES or sham control intervention during the first 5 weeks post-surgery.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
23
Inclusion Criteria
  • symptomatic, primary knee osteoarthritis (OA)
  • being considered for total knee arthroplasty
Read More
Exclusion Criteria
  • knee OA secondary to inflammatory/autoimmune disease
  • untreated/uncontrolled hypertension, diabetes or thyroid disease
  • chronic heart failure, actively-treated malignancy, exercise-limiting peripheral vascular disease, stroke or neuromuscular disease
  • body mass index >38 kg/m2
  • lower extremity blood clot or known coagulopathies
  • implanted pacemaker/ICD
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NMESNeuromuscular electrical stimulationNeuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
Primary Outcome Measures
NameTimeMethod
Intermyofibrillar mitochondrial contentChange from baseline cross-sectional area at 5 weeks

Area fraction of intermyofibrillar mitochondria will be assessed by electron microscopy

Cross-sectional area of muscle fibersChange from baseline cross-sectional area at 5 weeks

Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types

Mitochondrial functionChange from baseline cross-sectional area at 5 weeks

Oxygen consumption rate of isolated muscle mitochondria under adenosine diphosphate stimulation and hydrogen peroxide production

Maximal calcium-activated tension single muscle fiber tension and shortening velocityChange from baseline cross-sectional area at 5 weeks

Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition and shortening velocity will be evaluated from isotonic load clamps, with muscle fiber type determined post-measurement by gel electrophoresis

Secondary Outcome Measures
NameTimeMethod
Physical functional measuresChange from baseline cross-sectional area at 5 weeks

Whole body physical function will be assessed.

Whole muscle strengthChange from baseline cross-sectional area at 5 weeks

Knee extensor isometric and isokinetic strength will be assessed by dynamometry.

Quadriceps muscle cross-sectional areaChange from baseline cross-sectional area at 5 weeks

Quadriceps muscle cross-sectional area will be assessed by computed tomography at the mid-thigh.

Physical activity levelChange from baseline cross-sectional area at 5 weeks

Physical activity will be assessed by accelerometry.

Trial Locations

Locations (1)

University of Vermont College of Medicine

🇺🇸

Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath